Get the Stockscreener App
0.5158
3.32%
-0.0177
After Hours:
.51
-0.0058
-1.12%
Nkgen Biotech Inc stock is traded at $0.5158, with a volume of 745.41K.
It is down -3.32% in the last 24 hours and up +8.48% over the past month.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
See More
Previous Close:
$0.5335
Open:
$0.5289
24h Volume:
745.41K
Relative Volume:
0.21
Market Cap:
$23.18M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.77%
1M Performance:
+8.48%
6M Performance:
-33.53%
1Y Performance:
-39.25%
1-Day Range:
$0.5009
$0.5595
1-Week Range:
$0.4831
$0.5899
52-Week Range:
$0.2026
$4.06
Nkgen Biotech Inc Stock (NKGN) Company Profile
Name
Nkgen Biotech Inc
Sector
Industry
Phone
(949) 396-6830
Address
3001 DAIMLER ST,, SANTA ANA
Compare NKGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.5158 | 23.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkgen Biotech Inc Stock (NKGN) Latest News
Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech announces administration of first dose of troculeucel - TipRanks
NKGen Biotech Announces Administration of First Dose of - GlobeNewswire
Can NK Cell Therapy Help Stroke Patients? NKGen's FDA-Cleared Treatment Begins Testing - StockTitan
NKGen Biotech Doses First FTD Patient With Troculeucel Under FDA Compassionate Use - Nasdaq
NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia PatientWill NK Cells Change Neurology? - StockTitan
NKGen Biotech Inc (NKGN) At $0.48: It’s Worth Your Interest - Stocks Register
NKGen Appoints Dr. Anita Fletcher as National Principal - GlobeNewswire
NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer'S Disease With Adventhealth Orlando As First East Coast Site - Marketscreener.com
Can This NK Cell Therapy Transform Alzheimer's Treatment? Phase 1 Shows Remarkable 90% Success - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Midday Stock Roundup: RxSight Down 6.1% on Weak Post-3Q Results - Orange County Business Journal
FDA fast tracks NKGen's Alzheimer's therapy troculeucel - MSN
NKGen Biotech Announces Publication of Phase 1 Troculeucel - GlobeNewswire
Market cap of NKGen Biotech Inc [NKGN] reaches 37.83M – now what? - The DBT News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
NKGen's Troculeucel Therapy Demonstrates Stability And Cognitive Improvement In AD Trial - Nasdaq
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the ... - The Bakersfield Californian
Revolutionary Alzheimer's Treatment Shows Remarkable 90% Success in Phase 1 Trial - StockTitan
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket - Benzinga India
FDA Fast Track Designation Sends Biotech Soaring Mid-Week - The Globe and Mail
FDA fast tracks NKGen's Alzheimer's therapy troculeucel By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug - TradingView
NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate - Marketscreener.com
NKGen Biotech Receives U.S. FDA Fast Track Designation for - GlobeNewswire
Revolutionary NK Cell Therapy for Alzheimer's Disease Receives FDA Fast-Track Status - StockTitan
How to Use the Immune System Against Cancer and Alzheimer's, with Dr. Paul Song - upworthyscience.com
NKGen Biotech (NYSE:NKGN) Trading Up 9.5% – Time to Buy? - Defense World
Midday Stock Roundup: Alignment Healthcare Rises on Update - Orange County Business Journal
NKGen Biotech regains compliance with Nasdaq listing standards - Investing.com
NKGen Biotech secures $4.5M in convertible loan agreement - Investing.com India
NKGen Biotech secures $4.5M in convertible loan agreement By Investing.com - Investing.com Canada
NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – Here’s Why - Defense World
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - Asianet Newsable
NKGen Biotech Awards Stock Options to Executives - TipRanks
Head to Head Survey: HilleVax (NASDAQ:HLVX) versus NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech faces Nasdaq delisting over market value By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq delisting over market value - Investing.com
NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewswire
NKGen Biotech Secures $18M Bid for NKMax Acquisition, Expanding Global IP Rights - StockTitan
NKGen Biotech selected as preferred stalking horse bidder for NKMax - Nasdaq
NKGen Biotech faces Nasdaq compliance issue By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq compliance issue - Investing.com India
Nkgen Biotech Inc Stock (NKGN) Financials Data
There is no financial data for Nkgen Biotech Inc (NKGN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.13%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):